R&D channel feed – Endpoints News

R&D channel feed

Following FDA debacle in ’09, Motif lines up a new shot at approval for antibiotic iclaprim

8 years ago

Amicus’ latest positive update on Pompe drug hints at accelerated approval pitch

8 years ago

Pushing the positive in p=0.05, RedHill says it’s ready for a pivotal IBD test

8 years ago

On a roll, Rigel flags a positive PhII for its lead, late-stage drug fostamatinib

8 years ago

Researchers go after the Holy Grail in flu research with the first big study for a universal jab

8 years ago

Top trend #4: We’re coming to a tipping point on cancer R&D, and it may not be pretty

8 years ago

Sam Kulkarni takes the helm at CRISPR Therapeutics as founding CEO steps down

8 years ago

Biohaven skunked by a placebo in PhII/III flop for ataxia drug, shares slide

8 years ago

Ablynx spikes as PhIII aTTP study comes through with promising data, setting up an FDA application

8 years ago

The hep C pipeline shrivels as Merck dumps two next-gen combos, boosting leader Gilead

8 years ago

Zogenix rockets up as PhIII study offers impressive data on Dravet syndrome, vaulting over a rival

8 years ago

Eli Lilly R&D chief Jan Lundberg heads for the exit as CEO assembles a new team at the top

8 years ago

Prothena carefully explains why it's killing a psoriasis drug after PhIb

8 years ago

After getting crushed by bad data, Zynerba says its cannabis-based drug worked on Fragile X symptoms

8 years ago

Open water: NIBR chief Jay Bradner partners with UC Berkeley on protein drug research institute

8 years ago

EMA warns HQ move may cause major turmoil, seriously delaying new drug approvals

8 years ago

Axovant's lead Alzheimer's drug flops in PhIII, ending an unlikely quest

8 years ago

Genocea shelves its lead drug, slashes staff and switches focus to trendy neoantigens

8 years ago

ProQR spotlights the most encouraging results from a mixed snapshot of efficacy for cystic fibrosis

8 years ago

J&J lines up its 4-in-1 HIV pill for FDA behind rivals from Gilead, GSK

8 years ago

Puretech’s Gelesis flunks the FDA’s key measure of success for weight loss treatments

8 years ago

Visualize: What would these 11 biotech companies look like without immigrants?

8 years ago

Two years on, Allergan’s $1.7B NASH drug still looks weak — at best

8 years ago

AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs

8 years ago

First page Previous page 290 291 292293294 295 296 Next page Last page